Form 4: Nuvation Bio Director Robert Mashal Reports Stock Purchases

Robert Mashal, a director at Nuvation Bio Inc., reported purchasing shares of Class A Common Stock through a trust.

Summary

• On April 1, 2025, Robert Mashal, a director of Nuvation Bio Inc., reported the purchase of Nuvation Bio Inc. Class A Common Stock.
• The purchases were made through the Robert D. Mashal 2020 Revocable Trust, for which Mashal serves as the sole trustee.
• The trust acquired 1,100 shares at $1.6655 per share and 98,900 shares at $1.6699 per share.
• Following these transactions, the trust beneficially owns 200,000 shares of Nuvation Bio Inc. Class A Common Stock.
• Mashal has granted power of attorney to Philippe Sauvage, Moses Makunje, and Stephen Dang to handle SEC filings related to Nuvation Bio Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock purchases by a director. The purchase itself could be seen as slightly positive, but the filing is routine.

Positives

• Director's purchase may signal confidence in the company.

Industry Context

Form 4 filings are standard practice for company insiders reporting transactions in their company's stock, providing transparency to investors.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis to gauge management's sentiment and potential future performance.
• Comparing the size and frequency of insider purchases with those of peers in the biotechnology industry can provide additional context.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Nuvation Bio, Robert Mashal, Form 4, Stock Purchase, Director, Beneficial Ownership, Class A Common Stock, SEC Filing